Frontlight ResearchEarly access
Vitiligo trials in Hong Kong
1 of 1 trials · From ClinicalTrials.gov, checked 15 November 2026. Ask the study team whether a trial fits you.
- Phase 2/3Taking peopleTopical Ruxolitinib for Face and Neck Vitiligo of Adult Chinese Patients Refractory to Topical Tacrolimus
- Where
- Hong Kong
- Age
- 18 years to 85 years
- People
- 20
- Run by
- Hospital Authority, Hong Kong
See details and how to joinNCT06719024